1Administer an antidiarrheal and continue bevacizumab because abdominal cramping is an expected adverse effect.
2Hold bevacizumab, notify the provider urgently, keep the client NPO, and prepare for imaging and surgical evaluation.✓ Correct answer
3Increase oral fluids and fiber, then reassess the abdominal pain at the next treatment visit.
4Apply a heating pad and administer a laxative to relieve suspected medication-related constipation.
Explanation
Sudden severe abdominal pain, guarding, fever, and bleeding in a client receiving bevacizumab require emergency evaluation for gastrointestinal perforation. The nurse should stop or hold the drug, notify the provider urgently, keep the client NPO, support circulation, and prepare for imaging and surgical consultation. Bevacizumab labeling requires discontinuation when gastrointestinal perforation is diagnosed. Antidiarrheals, laxatives, heat, or delayed reassessment can worsen harm.
Clinical reasoning VEGF inhibition impairs vascular and tissue repair and carries a serious risk of gastrointestinal perforation and fistula. Peritoneal findings are not routine diarrhea.
Decision rule With suspected perforation during bevacizumab therapy, stop exposure, keep the client NPO, stabilize, and obtain urgent diagnostic and surgical evaluation.
Scenario A client receiving bevacizumab develops sudden severe abdominal pain, guarding, fever, and bloody stool.
Gastrointestinal perforation — A full-thickness defect in the gastrointestinal wall that can cause peritonitis, sepsis, and life-threatening bleeding.
Bevacizumab toxicity — Serious VEGF-inhibitor adverse effects that include perforation, hemorrhage, hypertension, thrombosis, and impaired wound healing.
Pre-surgical hold — Hold bevacizumab 4-6 weeks before surgery and resume after wound healing.